Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383882 | 0.85 | — | — | |
| SCHEMBL386228 | 0.83 | — | — | |
| SCHEMBL3163922 | 0.82 | ACE2 (0.47) | TSHRLMNAACE2 | |
| SCHEMBL27890636 | 0.82 | ACE2 (0.42) | TSHRLMNAACE2 | |
| SCHEMBL6650910 | 0.82 | ACE2 (0.47) | TSHRLMNAACE2 | |
| SCHEMBL2118221 | 0.81 | ACE2 (0.36) | TSHRLMNAACE2 | |
| SCHEMBL28922715 | 0.79 | ACE2 (0.44) | LMNAACE2 | |
| SCHEMBL4449776 | 0.78 | TSHR (0.40) | TSHRLMNAACE2 | |
| SCHEMBL1905864 | 0.76 | TSHR (0.52) | TSHRLMNAACE2 | |
| SCHEMBL1410797 | 0.76 | TSHR (0.52) | TSHRLMNAACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118139926-A | Resin composition | 株式会社可乐丽 | 2024-06-04 | — | — | CN | disclosed |
| CN-118139909-A | Beta-methyl-delta-valerolactone based polymer | 株式会社可乐丽 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023068348-A1 | RESIN COMPOSITION | 株式会社クラレ | 2023-04-27 | — | — | WO | disclosed |
| WO-2023068346-A1 | Β-METHYL-δ-VALEROLACTONE POLYMER | 株式会社クラレ | 2023-04-27 | — | — | WO | disclosed |
| WO-2023068345-A1 | Β-METHYL-δ-VALEROLACTONE POLYMER | 株式会社クラレ | 2023-04-27 | — | — | WO | disclosed |
| EP-2444401-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8569504-B2 | Imidazopyridine compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2444401-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | CMA1, ACE, ALPI | TSHR 4076/4885LMNA 1000/4885ACE2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.